The FDA has approved Imuldosa, a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The following is a summary of “Single cell sequencing delineates T-cell clonality and pathogenesis of the parapsoriasis ...

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two ...

FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development, testing, and manufacturing solutions provider ...

On the most recent episode of The Breakdown with Bethany, actress and television personality La La Anthony shared her ...

Best Itchy Scalp Treatments. Sometimes a dry, itchy scalp is better treated with a prescription like Zoryve, a medication for ...

A major clinical trial shows home-based UV-B phototherapy is as effective as office treatments for psoriasis, offering ...

HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001.

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

Research further shows a significant association between patients with psoriasis and an increased incidence of obstructive ...

The number of patients with the condition is projected to expand significantly in the coming years as increasing awareness and healthcare spending worldwide leads to additional diagnoses. Organon is ...

UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more ...